(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 97.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
X4 Pharmaceuticals's revenue in 2026 is $9,014,000.On average, 7 Wall Street analysts forecast XFOR's revenue for 2026 to be $923,578,463, with the lowest XFOR revenue forecast at $665,519,775, and the highest XFOR revenue forecast at $1,069,585,353. On average, 7 Wall Street analysts forecast XFOR's revenue for 2027 to be $987,055,619, with the lowest XFOR revenue forecast at $600,816,464, and the highest XFOR revenue forecast at $1,287,463,850.
In 2028, XFOR is forecast to generate $7,670,077,679 in revenue, with the lowest revenue forecast at $1,571,366,135 and the highest revenue forecast at $18,182,950,995.